BMY 25282

BMY 25282 (BL 6782) is a mitomycin C (MMC) analog. BMY 25282 catalyzes oxygen activation in hepatocytes. BMY 25282 overcomes MMC tolerance in colon cancer cells and mouse models of colon cancer. BMY 25282 inhibits tumor growth in mouse models of leukemia and melanoma. BMY 25282 can be used in research on cancers such as leukemia, melanoma, and colon cancer[1][2][3].

Product Specifications

CAS Number

[88949-01-3]

Product Name Alternative

BL 6782

UNSPSC

12352005

Target

Others

Related Pathways

Others

Field of Research

Cancer

Smiles

CO[C@]12N(C[C@H]3[C@@H]2N3)C4=C(C(C(/N=C/N(C)C)=C(C)C4=O)=O)[C@H]1COC(N)=O

Molecular Formula

C18H23N5O5

Molecular Weight

389.41

References & Citations

[1]Silva JM, et al. Contrasting molecular cytotoxic mechanisms of mitomycin C and its two analogs, BMY 25282 and BMY 25067, in isolated rat hepatocytes. Biochem Pharmacol. 1993 Jun 9;45 (11) :2303-9. |[2]Willson JK, et al. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells. Cancer Res. 1985 Nov;45 (11 Pt 1) :5281-6.|[3]Bradner WT, et al. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative. Cancer Res. 1985 Dec;45 (12 Pt 1) :6475-81.